Immunic, Inc. (NASDAQ:IMUX) Short Interest Update

Immunic, Inc. (NASDAQ:IMUX) was the recipient of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 4,190,000 shares, an increase of 10.3% from the November 15th total of 3,800,000 shares. Based on an average trading volume of 885,100 shares, the days-to-cover ratio is presently 4.7 days.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on IMUX. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. B. Riley assumed coverage on shares of Immunic in a research note on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price target for the company. HC Wainwright initiated coverage on shares of Immunic in a research report on Monday, November 25th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $11.80.

Immunic Trading Down 1.8 %

Shares of NASDAQ:IMUX opened at $1.11 on Tuesday. The firm has a 50 day simple moving average of $1.27 and a 200-day simple moving average of $1.34. Immunic has a twelve month low of $0.97 and a twelve month high of $2.11. The company has a market capitalization of $99.99 million, a PE ratio of -0.90 and a beta of 1.89.

Insider Transactions at Immunic

In other Immunic news, Director Richard Alan Rudick purchased 87,300 shares of the business’s stock in a transaction on Tuesday, November 12th. The shares were bought at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the purchase, the director now directly owns 87,300 shares of the company’s stock, valued at approximately $100,395. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Immunic

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in shares of Immunic in the third quarter valued at approximately $50,000. Jane Street Group LLC boosted its stake in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares during the period. State Street Corp grew its position in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares during the period. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.